Transdermal Drug in Adhesive Delivery Patch A Technology Outline CC Lee M.Sc.,B.Sc.(Hons) CEO, Director of Technology
Transdermal Drug Delivery Offers the Best of IV and Oral Administration IV Oral TDD Reduced liver first-pass effects No Constant drug levels No Self-administration No Unrestricted patient activity No Non-invasive No
Transdermal Delivery is a more effective route 100% Transdermal Route Oral Route 90% 80% 70% 60% 50% 40% 30% 20% 10% Permission of Medilynk 0%
Commercialized TDDP products
Global TDD Market 50 45 40 35 30 25 20 15 10 5 0 Market Size (Billion USD) 2005 2010 2015 2020 Source: Jain Pharma Biotech Strategic Report (October 2006)
Design of a Transdermal Patch - Adhesive-Matrix Patch Adhesive + Drug + Excipient Backing Skin
Design of a Transdermal Patch - Polymer-Matrix Patch Polymer + Drug + Excipients Backing Adhesive Skin
Basic Building Blocks of TDDP Manufacturing Drug Development & Formulation (Pharmaceutical & Biotech Expertise) Excipients & Enhancer Development (Formulation & Transdermal Chemistry) Adhesive Development & Formulation Materials engineering & Analytical capability Manufacturing & Process Capability TDD Patch Manufacture Medical & Cosmetic Product Business Pharmaceutical / & Biotech Drug Companies Regulatory Affairs Drug Development Capability PSA Materials Capability
Typical Matrix Patch Manufacturing Process Drug in Adhesive Compounding Active Pharmaceutical Ingredients supply Enhancer Encapsulation Patch Manufacturing Patch Packaging Patch Converting
Typical TDDP Product Development Cycle
Transdermal Technologies Transdermal Technology Passive Diffusion Thermal Chemical Permeation Enhanced Liposome / (Encapsulation) Magnetophoresis / (Magnetic field) Iontophoresis / (Electrical charge) Sonophoresis / (Ultra sound) Microporation / (Micro needle) Mode Passive Active Passive Passive Active Active Active Active Molecular Weight Dalton (g/mole) <500 <500 <500?????? No Limits No Limits No Limits
Examples of Transdermal Enhancer Technologies Glucosamine (water soluble) Medilynk proprietary Zip Bi-layer Liposome Technology Natural Oils (proprietary formula & process) Phospholipids (cell membrane) Membrane Permission of Medilynk
Current Scope of TDDP Therapeutic Application Hormone Replacement Therapy (HRT) Estrogen Replacement Therapy (ERT) Cardiovascular Oral Contraception Pain Management Asthma/Respiratory Smoking Cessation/Addiction Medication Urinary Incontinence/Gastro-Urinary Antiemetics Nutrition Cosmetics Sports Medicine Immunization
Strong Pharmaceutical Advisory & PSA Materials Engineering Support to products solutions Principal Consultant LEE Chee Cheow M.Sc.,., B.Sc.(Hons). Chief Executive Officer IABPI Pte. Ltd. LEVERA Pte Ltd. We provide: Pharmaceutical expertise in TDD formulation and clinical validation. Leading edge emulsion based transdermal drug delivery platform with continuous development & improvements. TDD Patch manufacturing is back up by solid PSA label materials manufacturing expertise. Chief Scientific Advisor: Dr. LEE Chee Wee Associate Professor Department of Physiology National University Singapore Chief Executive Officer Lynk Biotechnologies Pte Ltd.